PTC Therapeutics
PTCT
213 hedge funds and large institutions have $3.83B invested in PTC Therapeutics in 2022 Q3 according to their latest regulatory filings, with 50 funds opening new positions, 73 increasing their positions, 62 reducing their positions, and 17 closing their positions.
194% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 17
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
29% more capital invested
Capital invested by funds: $2.97B → $3.83B (+$857M)
18% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 62
18% more funds holding
Funds holding: 181 → 213 (+32)
2.71% more ownership
Funds ownership: 103.89% → 106.59% (+2.7%)
21% less call options, than puts
Call options by funds: $8.95M | Put options by funds: $11.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$28.2M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$26.2M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$22.4M |
| 4 |
Millennium Management
New York
|
+$21.6M |
| 5 |
Two Sigma Investments
New York
|
+$15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$39.3M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$21.7M |
| 3 |
AC
Armistice Capital
New York
|
-$19.4M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$13.2M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.52M |
PTCT Hedge Fund Activity: Q3 2022 in Review
213 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q3 2022, worth a combined $3.83B — up 29% from $2.97B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new PTCT positions and 17 closed out — a net gain of 33 holders — while 73 added to existing stakes and 62 trimmed.
The largest buyer was RTW Investments, adding an estimated $28.2M. The largest seller was State Street, cutting an estimated $39.3M.
- 213 institutional investors held PTC Therapeutics (PTCT) as of Q3 2022, up from 181 in Q2 2022.
- Funds reported $3.83B of PTC Therapeutics stock for Q3 2022, up 29% quarter-over-quarter.
- 50 funds opened new PTC Therapeutics positions in Q3 2022 and 17 closed out, a net change of +33 holders.
- The largest PTC Therapeutics buyer in Q3 2022 was RTW Investments, an estimated $28.2M added.
- The largest PTC Therapeutics seller in Q3 2022 was State Street, an estimated $39.3M sold.
Based on aggregated 13F filings for Q3 2022.